Introduction {#sec1-2152656719860820}
============

The dual role of allergy in cancer prevention or cancer development is highly controversial over the past few decades. Several hypotheses have been put forward to explicit the controversial findings.

It is proposed that allergic disorders could protect the body against cancer development via promoting the "immune surveillance,"^[@bibr1-2152656719860820]^ which states that the immune system is able to detect and eliminate malignant cells more effectively in a hypersensitive state such as allergy. In immunoglobulin E (IgE)-mediated allergies, high level of IgE could bind to the tumor-specific antigens and facilitate the antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis mechanisms.^[@bibr2-2152656719860820]^ Moreover, IgE could stimulate the production of reactive oxygen metabolites and nitric oxide, which are important in tumor eradication.^[@bibr3-2152656719860820]^

Another theory which declares the protective role of allergic disorders in cancer development is prophylaxis theory.^[@bibr1-2152656719860820],[@bibr4-2152656719860820]^ This theory explains that allergic reactions could prophylactically expel toxins, microorganisms, or environmental particles that may contain carcinogens from the body.^[@bibr5-2152656719860820]^ The decreased risk of brain and lung cancers in some epidemiological studies supports this hypothesis.^[@bibr6-2152656719860820][@bibr7-2152656719860820]--[@bibr8-2152656719860820]^

In contrast to the previous theories, the antigenic stimulation theory supports a positive association between history of allergic disorders and the risk of cancer. It suggests that inflammatory conditions associated with the allergic diseases may induce oxidative damage.^[@bibr9-2152656719860820]^ The oxidative damage cause mutations in the genes that are involved in cell cycle, DNA damage repair, and apoptosis, increasing the risk of cancer development.^[@bibr1-2152656719860820],[@bibr10-2152656719860820],[@bibr11-2152656719860820]^ Another recent hypothesis proposes that the recurrent injury and repair processes in the chronic inflammatory condition associated with an allergy could eventually skew T-lymphocyte response from T-helper 1 (Th1) toward Th2, which implies an important role in carcinogenesis.^[@bibr10-2152656719860820]^ Th1 cells are associated with the suppression and eradication of tumor disease, and Th-2 cells are involved in the allergy and parasite diseases. Skewed immune system toward Th2 in the long term is associated with the suppression of immune system, which is involved in the tumor suppression. Th2 polarization could increase the systemic level of types 2 cytokines such as interleukin (IL)-4, IL-5, and IL-13 or cause the systemic suppression of interferon-γ, IL-12, and IL-18, which are important in tumor eradication.^[@bibr12-2152656719860820]^

Recent studies demonstrated that the association between history of allergic disorders and the risk of cancer varied by types of cancer.^[@bibr13-2152656719860820][@bibr14-2152656719860820][@bibr15-2152656719860820]--[@bibr16-2152656719860820]^ An inverse association between allergy markers and risk of colorectal cancer, pancreatic cancer, and larynx cancer; a direct association for lymphoma, prostate cancer, and myeloma; and controversial results in breast cancer (BC) and lung cancer have been reported in several studies.^[@bibr10-2152656719860820],[@bibr16-2152656719860820][@bibr17-2152656719860820]--[@bibr18-2152656719860820]^

In addition, the complex findings show that the allergy--cancer relationship is not only governed by the specific cancer site but also with the specific allergic disorders. For instance, the risk of lung cancer significantly increased in patients with asthma-specific history, but no strong evidence was reported between lung cancer and the other types of allergic conditions.^[@bibr13-2152656719860820]^ Therefore, the role of different types of allergic disorders in each cancer type should be investigated specifically.

BC is the most commonly diagnosed cancer among women worldwide,^[@bibr19-2152656719860820],[@bibr20-2152656719860820]^ which imposes high financial burden to health-care systems.^[@bibr21-2152656719860820]^ A negative association,^[@bibr22-2152656719860820],[@bibr23-2152656719860820]^ a positive association,^[@bibr24-2152656719860820][@bibr25-2152656719860820]--[@bibr26-2152656719860820]^ and no association^[@bibr27-2152656719860820]^ relating to the allergic disorders and risk of BC have been reported in the several studies. These conflicting results may be due to the pleiotropic nature of allergic immunity or different methods of measurement in the epidemiological studies. To best of our knowledge, no comprehensive study had been conducted to clarify the association between different types of allergic disorders and the risk of BC. Therefore, this review was designed to be more focus on BC and present and discuss all published epidemiological studies concerning the effect of atopy and different types of allergic disorders in the risk of BC. Moreover, we have tried to explore the immunological mechanism, mainly, the role of Th2-type immune system, behind this association.

History of Any Allergic Condition {#sec2-2152656719860820}
---------------------------------

A positive association between combined history of any allergic condition and risk of BC has been observed consistently in the cohort studies,^[@bibr25-2152656719860820],[@bibr26-2152656719860820],[@bibr28-2152656719860820]^ although the results did not reach statistically significant ([Table 1](#table1-2152656719860820){ref-type="table"}). The cohort of Sweden reported a history of any allergy could increase the risk of BC by 50% (standardized incidence rate \[SIR\]: 1.5; 95% confidence interval \[CI\], 0.8--2.6).^[@bibr28-2152656719860820]^ Similarity, a slightly elevated risk of BC was detected in 2 cohort studies conducted in the United States.^[@bibr25-2152656719860820],[@bibr26-2152656719860820]^

###### 

Studies of the Association Between History of Any Types of Allergic Disorder and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table1)

  Studies                                        Country   Study Design    Sample Size                          How Allergies Are Defined                    RR/OR/SIR/HR/SMR (95% CI)                                                                                        Main Finding                                                                             Reference Group                                           Confounding Factors
  ---------------------------------------------- --------- --------------- ------------------------------------ -------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------
  Shirkhoda et al.^[@bibr29-2152656719860820]^   Iran      Case--control   Case (168)Control (165)              Physician-diagnosed or ISAAC questionnaire   OR: 1.0 (0.6--1.7)                                                                                               No association                                                                           No history of allergy                                     Yes^[a](#table-fn3-2152656719860820){ref-type="table-fn"}^
  Lowcock et al.^[@bibr23-2152656719860820]^     Canada    Case--control   Case (3101)Control (3471)            Physician-diagnosed                          All participant: **OR: 0.9 (0.8--1.0)**Premenopausal: OR: 0.9 (0.7--1.1)Postmenopausal: **OR: 0.8 (0.7--1.0)**   All participant: reduced riskPremenopausal: no associationPostmenopausal: reduced risk   No history of allergy                                     Yes^[b](#table-fn4-2152656719860820){ref-type="table-fn"}^
  Wang et al.^[@bibr16-2152656719860820]^        Germany   Case--control   Case (381)Control (2367)             Physician-diagnosed                          OR: 1.1 (0.8--1.6)                                                                                               No association                                                                           No atopy (no specific/total IgE positive)                 Yes^[c](#table-fn5-2152656719860820){ref-type="table-fn"}^
  Hedderson et al.^[@bibr30-2152656719860820]^   USA       Case--control   Cases (723) Controls (958)           Physician-diagnosed                          Overall: OR: 0.9 (0.8--1.1)Age \<35 years: OR: 1.3 (0.9--1.8)Age \>35 years: **OR: 0.8 (0.6--0.1)**              Overall: no associationAge \<35 years: increased riskAge \>35 years: reduced risk        No history of allergy                                     Age, smoking and education
  Eriksson et al.^[@bibr28-2152656719860820]^    Sweden    Cohort          Participant with any allergy (N/S)   Self-reported symptoms                       SIR: 1.5 (0.8--2.6)                                                                                              Increased risk                                                                           Incidence rate in the general population in the country   No
  Mills et al.^[@bibr26-2152656719860820]^       USA       Cohort          Participant with any allergy (N/S)   Self-reported                                RR: 1.2 (0.9--1.6)                                                                                               Increased risk                                                                           No history of allergy                                     Yes^[d](#table-fn6-2152656719860820){ref-type="table-fn"}^
  McWhorter^25^                                  USA       Cohort          Participant with any allergy (N/S)   Physician-diagnosed                          ROR: 1.2 (0.6--2.4)                                                                                              Increased risk                                                                           No history of allergy                                     Yes^[e](#table-fn7-2152656719860820){ref-type="table-fn"}^

Abbreviations: CI, confidence interval; HR, hazard ratio; IgE, Immunoglobulin E; ISAAC, International Study of Asthma and Allergies in Childhood; N/S, not specified; OR, odds ratio; ROR, risk OR; RR, relative risk; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^Age, breast-feeding time (month), parity, family history of breast and ovarian cancer, and smoking.

^b^Body mass index, smoking, physical activity, education, income, country of birth, and ethnicity.

^c^Age, education, body mass index, family history of cancer, cigarette smoking and alcohol consumption, menopausal status, use of hormone replacement, and age at first full-term pregnancy.

^d^Age, age at menarche, first pregnancy, menopause, education, maternal history of breast cancer, smoking, and time since last physician contact.

^e^Age, race, sex, and smoking status; number of pregnancies; and Quetelet's index.

In contrast, case--control studies did not clearly indicate a history of any allergic condition as a risk factor for BC developments. A case--control study designed in Canada found a significant small reduction in the risk of BC (odds ratio \[OR\]: 0.9; 95% CI, 0.8--1.0) among participant with history of any types of allergic disorders.^[@bibr23-2152656719860820]^ The other case--control studies reported no association between asthma and the risk of BC.^[@bibr16-2152656719860820],[@bibr29-2152656719860820],[@bibr30-2152656719860820]^

History of Asthma {#sec3-2152656719860820}
-----------------

With 1 exception,^[@bibr29-2152656719860820]^ the epidemiological studies reported no strong association or a positive association between history of asthma and the risk of BC ([Table 2](#table2-2152656719860820){ref-type="table"}).^[@bibr23-2152656719860820],[@bibr27-2152656719860820],[@bibr31-2152656719860820][@bibr32-2152656719860820][@bibr33-2152656719860820][@bibr34-2152656719860820][@bibr35-2152656719860820]--[@bibr36-2152656719860820]^

###### 

Studies of the Association Between History of Asthma and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table2)

  Studies                                             Country     Study Design    Sample Size                         How Allergies Are Defined                                                                            RR/OR/SIR/HR/SMR (95% CI)                                                                                Main Finding                                                                               Reference Group                                                                          Confounding Factors
  --------------------------------------------------- ----------- --------------- ----------------------------------- ---------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- --------------------------------------------------------------
  Shirkhoda et al.^[@bibr29-2152656719860820]^        Iran        Case--control   Case (168)Control (165)             Physician-diagnosed or ISAAC questionnaire^[a](#table-fn10-2152656719860820){ref-type="table-fn"}^   **OR: 0.5 (0.2--1.0)**                                                                                   Reduced risk                                                                               No history of asthma                                                                     Yes^[b](#table-fn11-2152656719860820){ref-type="table-fn"}^
  Lowcock et al.^[@bibr23-2152656719860820]^          Canada      Case--control   Case (3101)Control (3471)           Physician-diagnosed                                                                                  All participant: OR: 1.0 (0.9--1.2)Premenopausal: OR: 0.7 (0.5--1.0)Postmenopausal: OR: 1.1 (0.9--1.4)   All participant: no associationPremenopausal: reduced riskPostmenopausal: no association   No history of asthma                                                                     Yes^[c](#table-fn12-2152656719860820){ref-type="table-fn"}^
  Hwang et al.^[@bibr31-2152656719860820]^            Taiwan      Cohort          Participant with asthma (107 601)   Physician-diagnosed                                                                                  SIR: 1.0 (0.9--1.1)                                                                                      No association                                                                             Incidence rate in the general population in the country                                  Age
  Ji et al.^[@bibr32-2152656719860820]^               Sweden      Cohort          Participant with asthma (140 425)   Subjects who had hospital admission for asthma                                                       SIR: 1.0 (1.0--1.1)                                                                                      No association                                                                             Incidence rate in the general population in the country (excluding asthmatic)            Yes^[d](#table-fn13-2152656719860820){ref-type="table-fn"}^
  Wang et al.^[@bibr16-2152656719860820]^             Germany     Case--control   Case (381)Control (2367)            Physician-diagnosed                                                                                  OR: 1.2 (0.7--2.2)                                                                                       Increased risk                                                                             No atopy (no specific/total IgE positive)                                                Yes^[e](#table-fn14-2152656719860820){ref-type="table-fn"}^
  González-Pérez et al.^[@bibr33-2152656719860820]^   UK          Case--control   Case (827)Control (10 092)          Physician-diagnosed                                                                                  OR: 0.9 (0.8--1.1)                                                                                       No association                                                                             Incidence rate in the general population in the country (excluding asthmatic and COPD)   Age, BMI, smoking, alcohol intake, and certain comorbidities
  Turner et al.^[@bibr34-2152656719860820]^           USA         Cohort          Participant with asthma (26 097)    Self-reported                                                                                        RR: 1.1 (0.9--1.3)                                                                                       No association                                                                             No history of asthma and allergic rhinitis                                               Yes^[f](#table-fn15-2152656719860820){ref-type="table-fn"}^
  Talbot-Smith et al.^[@bibr27-2152656719860820]^     Australia   Cohort          Women with asthma (155)             Physician-diagnosed                                                                                  HR: 1.1 (0.5--2.6)                                                                                       No association                                                                             N/S                                                                                      Yes^[g](#table-fn16-2152656719860820){ref-type="table-fn"}^
  Eriksson et al.^[@bibr28-2152656719860820]^         Sweden      Cohort          Participant with asthma (2512)      Self-reported symptoms                                                                               SIR: 1.4 (0.6--2.7)                                                                                      Increased risk                                                                             Incidence rate in the general population in the country                                  No
  Vesterinen et al.^[@bibr35-2152656719860820]^       Finland     Cohort          Participant with asthma (78 000)    Physician-diagnosed                                                                                  SIR: 1.0 (0.9--1.1)                                                                                      No association                                                                             Incidence rate in the general population in the country                                  Age
  Mills et al.^[@bibr26-2152656719860820]^            USA         Cohort          Participant with asthma (N/S)       Physician-diagnosed                                                                                  RR: 1.2 (0.7--2.0)                                                                                       Increased risk                                                                             No history of allergy                                                                    Yes^[h](#table-fn17-2152656719860820){ref-type="table-fn"}^
  Vena et al.^[@bibr36-2152656719860820]^             USA         Case--control   Case (1835)Control (2500)           Physician-diagnosed                                                                                  OR: 1.0                                                                                                  No association                                                                             N/S                                                                                      Age and smoking

Abbreviations: BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IgE, Immunoglobulin E; ISAAC, International Study of Asthma and Allergies in Childhood; N/S, not specified; OR, odds ratio; RR, relative risk; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^"Have you had wheezing or whistling in the chest in the last 12 months?" OR "Did a doctor ever tell you that you had respiratory allergies?"

^b^Age, breast-feeding time (month), parity, family history of breast and ovarian cancer, and smoking.

^c^BMI, smoking, physical activity, education, income, country of birth, and ethnicity.

^d^5-year age, gender, period (5-year group), socioeconomic status, and residential area.

^e^Age, education, BMI, family history of cancer, cigarette smoking and alcohol consumption, menopausal status, use of hormone replacement, and age at first full-term pregnancy.

^f^Race, smoking, education, BMI, exercise, alcohol drinking, use of oral contraceptives, estrogen replacement therapy, age at first birth, age at menarche, age at menopause, height, and family history of breast cancer.

^g^Age, smoking status, BMI, number of pregnancies, and menopausal status.

^h^Age, age at menarche, first pregnancy, menopause, education, maternal history of breast cancer, smoking, and time since last physician contact.

A nonsignificant increased risk of BC among people with a history of physician-diagnosed asthma was observed in a case--control study in Germany (OR: 1.2; 95% CI, 0.7--2.2).^[@bibr16-2152656719860820]^ Likewise, a cohort study designed in Sweden demonstrated 40% increased incidence risk of BC (SIR: 1.4; 95% CI, 0.6--2.7).^[@bibr28-2152656719860820]^ In this cohort study, individuals who reported symptoms such as dyspnea or wheezing on exposure to allergens were classified as bronchial asthmatic participants. Another study conducted in the United States reported a nonsignificant positive association between BC incidence rate and history of physician-diagnosed asthma (relative risk \[RR\]: 1.2; 95% CI, 0.7--2.0).^[@bibr26-2152656719860820]^

The other epidemiological studies reported no association between asthma and risk of BC. The asthmatic participants who were diagnosed by physician were included in these studies.^[@bibr23-2152656719860820],[@bibr27-2152656719860820],[@bibr31-2152656719860820][@bibr32-2152656719860820][@bibr33-2152656719860820][@bibr34-2152656719860820][@bibr35-2152656719860820]--[@bibr36-2152656719860820]^

History of Allergic Rhinitis {#sec4-2152656719860820}
----------------------------

The majority of the identified studies indicated a higher prevalence of allergic rhinitis among BC patients compared to the general population ([Table 3](#table3-2152656719860820){ref-type="table"}).

###### 

Studies of the Association Between History of AR and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table3)

  Studies                                           Country     Study Design    Sample Size                     How Allergies Are Defined                                                                            RR/OR/SIR/HR/SMR (95% CI)   Main Finding     Reference Group                                           Confounding Factors
  ------------------------------------------------- ----------- --------------- ------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------- ---------------- --------------------------------------------------------- -------------------------------------------------------------
  Shirkhoda et al.^[@bibr29-2152656719860820]^      Iran        Case--control   Case (168)Control (165)         Physician-diagnosed or ISAAC questionnaire^[a](#table-fn20-2152656719860820){ref-type="table-fn"}^   OR: 1.5 (0.7--3.0)          Increased risk   No history of AR                                          Yes^[b](#table-fn21-2152656719860820){ref-type="table-fn"}^
  Kozłowska et al.^[@bibr37-2152656719860820]^      Poland      Case--control   Case (231)Control (754)         Laryngological examinations, and history of clinical symptoms according to ARIA guidelines           **Significant OR**          Reduced risk     N/S                                                       N/S
  Hwang et al.^[@bibr31-2152656719860820]^          Taiwan      Cohort          Participant with AR (225 315)   Physician-diagnosed                                                                                  SIR: 1.2 (1.1--1.3)         Increased risk   Incidence rate in the general population in the country   Age
  Wang et al.^[@bibr16-2152656719860820]^           Germany     Case--control   Case (381)Control (4271)        Physician-diagnosed                                                                                  OR: 1.2 (0.8--1.8)          Increased risk   No atopy (no specific/total IgE positive)                 Yes^[c](#table-fn22-2152656719860820){ref-type="table-fn"}^
  Talbot-Smith et al.^[@bibr27-2152656719860820]^   Australia   Cohort          Participant with AR (597)       Physician-diagnosed                                                                                  HR: 0.9 (0.5--1.7)          No association   N/S                                                       Yes^[d](#table-fn23-2152656719860820){ref-type="table-fn"}^
  Eriksson et al.^[@bibr28-2152656719860820]^       Sweden      Cohort          Participant with AR (5006)      Self-reported symptoms                                                                               SIR: 1.5 (0.8--2.6)         Increased risk   Incidence rate in the general population in the country   No
  Mills et al.^[@bibr26-2152656719860820]^          USA         Cohort          Participant with AR (N/S)       Self-reported                                                                                        RR: 1.3 (1.0--1.9)          Increased risk   No history of allergy                                     Yes^[e](#table-fn24-2152656719860820){ref-type="table-fn"}^
  Vena et al.^[@bibr36-2152656719860820]^           USA         Case--control   Case (1835)Control (2500)       Physician-diagnosed                                                                                  OR: 0.9                     No association   N/S                                                       Age and smoking

Abbreviations: AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on Asthma; CI, confidence interval; HR, hazard ratio; IgE, Immunoglobulin E; ISAAC, International Study of Asthma and Allergies in Childhood; N/S, not specified; OR, odds ratio; RR, relative risk; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^Answer yes to both "In the past 12 months, have you had a problem with sneezing, or a runny, or blocked nose when you DID NOT have a cold or the flu?" AND "In the past 12 months, has this nose problem been accompanied by itchy-watery eyes?"

^b^Age, breast-feeding time (month), parity, family history of breast and ovarian cancer, and smoking.

^c^Age, education, body mass index, family history of cancer, cigarette smoking and alcohol consumption, menopausal status, use of hormone replacement, and age at first full-term pregnancy.

^d^Age, smoking status, body mass index, number of pregnancies, and menopausal status.

^e^Age, age at menarche, first pregnancy, menopause, education, maternal history of breast cancer, smoking, and time since last physician contact.

Two cohort studies conducted in Taiwan^[@bibr31-2152656719860820]^ and the United States^[@bibr26-2152656719860820]^ found a history of diagnosed-physician rhinitis to be associated with an increased incidence rate of BC. In the cohort of the United States, the association was borderline statistical significance (RR: 1.3; 95% CI, 1.0--1.9). A Swedish cohort study, which considered rhinitis symptoms rather than physician-diagnosed, found a 50% increased incidence risk of BC (SIR: 1.5; 95% CI, 0.8--2.6).^[@bibr28-2152656719860820]^ However, it was not statistically significant. Similarity, in our recent case--control study, we found 50% increased odds of BC (OR: 1.5; 95% CI, 0.7--3.0).^[@bibr29-2152656719860820]^ We designed the first study that used International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire to consider the different types of allergic symptoms for better identification of patients with allergic rhinitis. Another case--control study in Germany found that physician-diagnosed positive history is associated with nonsignificant increased risk of BC (OR: 1.2, 95% CI, 0.8--1.8).^[@bibr16-2152656719860820]^

Inconsistent results appeared from the recent study conducted in Poland, reporting allergic rhinitis was significantly less prevalent in patients with BC.^[@bibr37-2152656719860820]^ However, the authors did not adjust the potential confounding factors. In their study, allergic rhinitis was defined by laryngological examinations and history of clinical symptoms according to Allergic Rhinitis and its Impact on Asthma guidelines.

In addition, some studies found no association between history rhinitis and BC. In Busselton's cohort study (hazard ratio \[HR\]: 0.9; 95% CI, 0.51--1.7)^27^ and U.S. case--control study (OR: 0.9),^[@bibr36-2152656719860820]^ no correlation reported between physician-diagnosed positive history and risk of BC.

History of Atopic Dermatitis {#sec5-2152656719860820}
----------------------------

With 1 exception, epidemiological studies indicated that individuals with a history of atopic dermatitis have an elevated risk of BC, although all results did not reach statistically significant ([Table 4](#table4-2152656719860820){ref-type="table"}).

###### 

Studies of the Association Between History of AD and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table4)

  Studies                                        Country   Study Design    Sample Size                    How Allergies Are Defined                                                                            RR/OR/SIR/HR/SMR (95% CI)   Main Finding     Reference Group                                           Confounding Factors
  ---------------------------------------------- --------- --------------- ------------------------------ ---------------------------------------------------------------------------------------------------- --------------------------- ---------------- --------------------------------------------------------- -------------------------------------------------------------
  Shirkhoda et al.^[@bibr29-2152656719860820]^   Iran      Case--control   Case (168)Control (165)        Physician-diagnosed or ISAAC questionnaire^[a](#table-fn27-2152656719860820){ref-type="table-fn"}^   OR: 1.3 (0.5--3.1)          Increased risk   No history of AD                                          Yes^[b](#table-fn28-2152656719860820){ref-type="table-fn"}^
  Hwang et al.^[@bibr31-2152656719860820]^       Taiwan    Cohort          Participant with AD (34 263)   Physician-diagnosed                                                                                  SIR: 1.2 (0.8--1.6)         Increased risk   Incidence rate in the general population in the country   Age
  Wang et al.^[@bibr16-2152656719860820]^        Germany   Case--control   Case (381)Control (4271)       Physician-diagnosed                                                                                  OR: 1.0 (0.5--1.9)          No association   No atopy (no specific/total IgE positive)                 Yes^[c](#table-fn29-2152656719860820){ref-type="table-fn"}^
  Olesen et al.^[@bibr38-2152656719860820]^      Denmark   Cohort          Participant with AD (2030)     Physician-diagnosed                                                                                  SMR: 1.4 (0.7--2.7)         Increased risk   Incidence rate in the general population in the country   N/S

Abbreviations: AD, atopic dermatitis; CI, confidence interval; HR, hazard ratio; IgE, Immunoglobulin E; ISAAC, International Study of Asthma and Allergies in Childhood; N/S, not specified; OR, odds ratio; RR, relative risk; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^Answered yes to both "Have you had itchy rash at any time in the last 12 months?" AND "Has this itchy rash at any time affected the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes?"

^b^Age, breast-feeding time (month), parity, family history of breast and ovarian cancer, and smoking.

^c^Age, education, body mass index, family history of cancer, cigarette smoking and alcohol consumption, menopausal status, use of hormone replacement, and age at first full-term pregnancy.

A cohort study conducted in Taiwan indicated a slightly increased risk of BC among subjects with a history of atopic dermatitis (SIR: 1.2; 95% CI, 0.8--1.6).^[@bibr31-2152656719860820]^ In their study, dermatitis disease had been diagnosed by a specialist. Moreover, a Danish cohort population-based study demonstrated 40% increased cancer prevalence among hospitalized children with atopic dermatitis (standardized mortality ratio: 1.4; 95% CI, 0.7--2.7).^[@bibr38-2152656719860820]^ A similar finding was observed in our recent case--control study.^[@bibr29-2152656719860820]^ We found an increased risk of BC among subjects who were diagnosed dermatitis by a doctor or have dermatitis symptoms according to ISAAC quesionnire (OR: 1.3; 95% CI, 0.5--3.1).

In contrast, a population-based case--control study in Germany found no association between physician-diagnosed atopic dermatitis and BC (OR: 1.0; 95% CI, 0.5--1.9).^[@bibr16-2152656719860820]^

History of Food and Drug Allergy {#sec6-2152656719860820}
--------------------------------

To date, few studies have investigated the association between history of food and drug allergies and the risk of BC, with inconsistency results ([Table 5](#table5-2152656719860820){ref-type="table"}).

###### 

Studies of the Association Between History of Food or Drug Allergy and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table5)

  Studies                                          Country   Study Design    Sample Size                           How Allergies Are Defined              RR/OR/SIR/HR/SMR (95% CI)                                                                         Main Finding                                                                        Reference Group              Confounding Factors
  ------------------------------------------------ --------- --------------- ------------------------------------- -------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ---------------------------- -------------------------------------------------------------
  Food allergy                                                                                                                                                                                                                                                                                                                                                               
   Shirkhoda  et al.^[@bibr29-2152656719860820]^   Iran      Case--control   Case (168)Control (165)               Physician-diagnosed or Self-reported   OR: 1.4 (0.7--3.0)                                                                                Increased risk                                                                      No history of food allergy   Yes^[a](#table-fn32-2152656719860820){ref-type="table-fn"}^
   Hedderson  et al.^[@bibr30-2152656719860820]^   USA       Case--control   Cases (723)Controls (958)             Physician-diagnosed                    Overall: OR: 0.8 (0.6--1.2)Age \<35 years: OR: 1.2 (0.7--2.1)Age \>35 years: OR: 0.7 (0.5--1.0)   Overall: reduced risk Age \<35 years: increased riskAge \>35 years: reduced risk    No history of allergy        Age, smoking and education
  Drug allergy                                                                                                                                                                                                                                                                                                                                                               
   Shirkhoda  et al.^[@bibr29-2152656719860820]^   Iran      Case--control   Case (168)Control (165)               Physician-diagnosed or Self-reported   OR: 0.6 (0.2--1.8)                                                                                Reduced risk                                                                        No history of drug allergy   Yes^[a](#table-fn32-2152656719860820){ref-type="table-fn"}^
   Hedderson  et al.^[@bibr30-2152656719860820]^   USA       Case--control   Cases (723)Controls (958)             Physician-diagnosed                    Overall: OR: 1.0 (0.8--1.3)Age \<35 years: OR: 1.3 (0.9--2.1)Age \>35 years: OR: 0.8 (0.6--1.2)   Overall: no associationAge \<35 years: increased riskAge \>35 years: reduced risk   No history of allergy        Age and education
   Mills et al.^[@bibr26-2152656719860820]^        USA       Cohort          Participant with drug allergy (N/S)   Self-reported                          RR: 1.0 (0.7--1.3)                                                                                No association                                                                      No history of allergy        Yes^[b](#table-fn33-2152656719860820){ref-type="table-fn"}^

Abbreviations: CI, confidence interval; HR, hazard ratio; N/S, not specified; OR, odds ratio; RR, relative risk; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^Age, breast-feeding time (month), parity, family history of breast and ovarian cancer, and smoking.

^b^Age, age at menarche, first pregnancy, menopause, education, maternal history of breast cancer, smoking, and time since last physician contact.

A population-based case--control study in the United States found lower prevalence of doctor-diagnosed food allergy among BC patients compared to the control group (OR: 0.8; 95% CI, 0.6--1.2).^[@bibr30-2152656719860820]^ However, a different pattern was observed among women 35 years or younger (OR: 1.2; 95% CI, 0.7--2.1) and women older than 35 years (OR: 0.7; 95% CI, 0.5--1.0) in the stratified analysis.^[@bibr30-2152656719860820]^ The authors considered "individuals with no history of any allergy" as the reference group in the case--control analysis, which was different from our recent study conducted in Iran.^[@bibr29-2152656719860820]^ In our case--control study, individuals with no history of food allergy was considered as the reference group, and we found that food allergy prevalence was higher among BC patients (OR: 1.4; 95% CI, 0.7--3.0), although it was not statistically significant, which might be due to small sample size.^[@bibr29-2152656719860820]^

Of the identified studies, which investigate the relationship between a history of drug allergy and BC, 2 studies found no association^[@bibr26-2152656719860820],[@bibr30-2152656719860820]^ and 1 study reported a nonsignificant decreased risk^[@bibr29-2152656719860820]^ ([Table 5](#table5-2152656719860820){ref-type="table"}).

A population-based case--control study^[@bibr30-2152656719860820]^ and a population-based cohort study^[@bibr26-2152656719860820]^ conducted in the United States reported no association between BC and physician-diagnosed drug allergy with OR: 1.0; 95% CI, 0.7--1.3 and RR: 1.0; 95% CI, 0.7--1.3, respectively. However, our recent case--control study in Iran found a history of drug allergy was associated with a nonsignificant decreased risk of BC (OR: 0.6; 95% CI, 0.2--1.8).^[@bibr29-2152656719860820]^

Total IgE Level {#sec7-2152656719860820}
---------------

The studies, which investigated the association between total IgE level and risk of BC, had varying outcomes ([Table 6](#table6-2152656719860820){ref-type="table"}). Two studies found a positive association,^[@bibr29-2152656719860820],[@bibr39-2152656719860820]^ 1 study reported an inverse association,^[@bibr40-2152656719860820]^ and 2 studies demonstrated no association.^[@bibr9-2152656719860820],[@bibr41-2152656719860820]^

###### 

Studies of the Association Between Total IgE and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table6)

  Studies                                          Country      Study Design      Sample Size                                   The Defined Cutoff   RR/OR/SIR/HR/SMR (95% CI)                                            Main Finding     Reference Group          Confounding Factors
  ------------------------------------------------ ------------ ----------------- --------------------------------------------- -------------------- -------------------------------------------------------------------- ---------------- ------------------------ -------------------------------------------------------------
  Shirkhoda et al.^[@bibr29-2152656719860820]^     Iran         Case--control     Case (168)Control (165)                       25 IU/mL             OR: 1.6 (0.9--2.7)                                                   Increased risk   IgE level\< 25 IU/mL     Yes^[a](#table-fn36-2152656719860820){ref-type="table-fn"}^
  Zhang et al.^[@bibr40-2152656719860820]^         China        Case--control     Case (102)Control (100)                       32.6 IU/mL           **OR: 0.5 (0.3--0.7)**                                               Reduced risk     IgE level\< 32.6 IU/mL   N/S
  Taghizadeh et al.^[@bibr9-2152656719860820]^     Netherland   Cohort            Participant with high total IgE level (N/S)   Continues variable   HR: 0.9 (0.5--1.6)                                                   No association   N/S                      Yes^[b](#table-fn37-2152656719860820){ref-type="table-fn"}^
  Vijayakumar et al.^[@bibr39-2152656719860820]^   India        Case--control     Case (166)Control (100)                       Continues variable   **Case: Mean ± SD: 65.4 ± 31.4** **Control: Mean ± SD: 9.4 ± 8.4**   Increased risk   \-\--                    No
  Alsabti^41^                                      Jordan       Cross-sectional   Case (31)Control (50)                         Continues variable   Case: Mean ± SD: 29.5 ± 0.8Control: Mean ± SD: 31.2 ± 0.8            No association   \-\--                    No

Abbreviations: CI, confidence interval; HR, hazard ratio; IgE, Immunoglobulin E; N/S, not specified; OR, odds ratio; RR, relative risk; SD, standard deviation; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^Age, breast-feeding time (month), parity, family history of breast and ovarian cancer, and smoking.

^b^Age, body mass index (all at the first survey), and place of residence.

Two case--control studies conducted in India^[@bibr39-2152656719860820]^ and Iran^[@bibr29-2152656719860820]^ found an association between total IgE level and increased risk of BC. In the Indian study, total IgE level significantly elevated in BC and the levels were found to increase with clinical stage.^[@bibr39-2152656719860820]^ In our recent study, total IgE level above 25 IU/mL was determined as borderline significantly associated with BC in univariate analysis (OR: 1.5; 95% CI, 1--2.3).^[@bibr29-2152656719860820]^ However, the association was not significant in multivariate analysis.

Inconsistent results appeared from the study in China, indicating a significantly reduced risk of BC cancer among participant with high IgE level (OR: 0.5; 95% CI, 0.3--0.7).^[@bibr40-2152656719860820]^ However, a cross-sectional study conducted in Jordan^[@bibr41-2152656719860820]^ and a cohort study in Netherland^[@bibr9-2152656719860820]^ detected no difference association between the level of total IgE and BC.

Specific IgE or Prick Test {#sec8-2152656719860820}
--------------------------

Most studies revealed an increased risk of BC among people with a positive history of atopic using IgE specific or prick test ([Table 7](#table7-2152656719860820){ref-type="table"}).

###### 

Studies of the Association Between Specific IgE and Prick Test and the Risk of Breast Cancer.

![](10.1177_2152656719860820-table7)

  Studies                                             Country      Study Design    Types of Allergen                                                                                                                                                                                                                     Sample Size                                      The Defined Cutoff               RR/OR/SIR/HR/SMR (95% CI)                    Main Finding                             Reference Group                                           Confounding Factors
  --------------------------------------------------- ------------ --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ -------------------------------- -------------------------------------------- ---------------------------------------- --------------------------------------------------------- -------------------------------------------------------------
  Specific IgE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
   Skaaby et al.^[@bibr43-2152656719860820]^          Denmark      Cohort          19 common inhalant allergens, mite, cat, grass, and birch                                                                                                                                                                             Patients with specific IgE positivity (14 849)   Specific IgE level ≥0.35 kU/l    **HR: 0.3 (0.1--0.8)**                       Reduced risk                             Mortality rate in the general population in the country   Yes^[a](#table-fn40-2152656719860820){ref-type="table-fn"}^
   Petridou et al.^[@bibr42-2152656719860820]^        Greece       Case--control   12 most prevalent allergens in Greece                                                                                                                                                                                                 Case (103)Control (103)                          Specific IgE level ≥ 0.35 kU/l   OR: 1.7 (1.0--3.1)                           Increased risk                           N/S                                                       Yes^[b](#table-fn41-2152656719860820){ref-type="table-fn"}^
   Wang et al.^[@bibr16-2152656719860820]^            Germany      Case--control   Pollen of timothy, rye, birch and mugwort, house dust mite, cat, dog, and *Cladosporium*                                                                                                                                              Case (381)Control (2367)                         Specific IgE level ≥ 0.35 kU/l   OR: 1.2 (0.9--1.7)                           Increased risk                           No atopy (no specific/total IgE positive)                 Yes^[c](#table-fn42-2152656719860820){ref-type="table-fn"}^
  Patch/prick test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Taghizadeh et al.^[@bibr9-2152656719860820]^       Netherland   Cohort          House dust, mixed pollen, epidermal products, and mixed molds                                                                                                                                                                         Participant with patch test positivity (N/S)     Positive patch test              Cancer hospitalization: HR: 1.0 (0.5--2.0)   Cancer hospitalization: no association   N/S                                                       Yes^[d](#table-fn43-2152656719860820){ref-type="table-fn"}^
   Engkilde et al.^[@bibr44-2152656719860820]^        Denmark      Cohort          23 allergens contained in the European Standard Screening Tray                                                                                                                                                                        Participant with patch test positivity (6065)    Positive patch test              **OR: 0.8 (0.7--1.0)**                       Reduced risk                             N/S                                                       Age
   Talbot-Smith  et al.^[@bibr27-2152656719860820]^   Australia    Cohort          House dust mites, cat dander, cattle dander, 2 molds (*Aspergillus fumigatus* and *Alternariae tenius*), and 7 local pollens (rye grass, barley, capeweed, orchard grass, plantago, peppermint tree, couchweed grass, and wild oat)   Participant with prick test positivity (239)     Positive prick test              HR: 1.4 (0.6--3.4)                           Increased risk                           N/S                                                       Yes^[e](#table-fn44-2152656719860820){ref-type="table-fn"}^
   Eriksson et al.^[@bibr28-2152656719860820]^        Sweden       Cohort          *Dermatophagoides pteronyssinus*, horse, dog, cat, timothy, mugwort, birch, and *Cladosporium*                                                                                                                                        Participant with prick test positivity (2435)    Positive prick test              **SIR: 2.5 (1.0--5.2)**                      Increased risk                           Incidence rate in the general population in the country   No

Abbreviations: CI, confidence interval; HR, hazard ratio; IgE, Immunoglobulin E; N/S, not specified; OR, odds ratio; RR, relative risk; SIR, standardized incidence rate; SMR, standardized mortality ratio.

Bold values indicate statistical significance.

^a^Education, season of blood sample, physical activity, smoking habits, alcohol intake, body mass index, systolic and diastolic blood pressure, serum triglycerides, and total cholesterol.

^b^Age, education, height, age at menarche, parity, age at menopause, and alcohol consumption.

^c^Age, education, body mass index, family history of cancer, cigarette smoking and alcohol consumption, menopausal status, use of hormone replacement, and age at first full-term pregnancy.

^d^Age, body mass index (all at the first survey), and place of residence.

^e^Age, smoking status, body mass index, number of pregnancies, and menopausal status.

Two case--control studies designed in Greece^[@bibr42-2152656719860820]^ and Germany^[@bibr16-2152656719860820]^ found high risk of BC in relation to the positive IgE specific with OR of 1.7, 95% CI, 1.0--3.1 and 1.2, 95% CI, 0.9--1.7, respectively. However, 1 population-based prospective study in Denmark reported no association (HR: 1.00; 95% CI, 0.73--1.37).^[@bibr43-2152656719860820]^ In all studies, the cutoff value for positivity of the specific IgE was considered as ≥0.35 kU/L.

In term of prick test, a cohort study designed in Sweden^[@bibr28-2152656719860820]^ reported a significantly elevated risk of BC among individuals with positive patch test (SIR: 2.5; 95% CI, 1.0--5.2) ([Table 7](#table7-2152656719860820){ref-type="table"}). Likewise, the cohort study in Australia reported nonsignificant high risk of BC (HR: 1.4; 95% CI, 0.6--3.4).^[@bibr27-2152656719860820]^ However, a significantly reduced risk of BC was reported in the study conducted in Denmark (OR: 0.8; 95% CI, 0.7--1.0).^[@bibr44-2152656719860820]^ Beside, a population-based cohort study in Netherlands showed no association between any types of atopic diseases and cancer hospitalization patients (OR: 1.0; 95% CI, 0.5--2.0).^[@bibr9-2152656719860820]^

Discussion {#sec9-2152656719860820}
==========

Most of the identified studies demonstrated nonsignificant results. However, the pattern of the results indicated an increased risk of BC in individuals with history of allergies. The majority of studies reported a higher prevalence of atopic dermatitis and allergic rhinitis among individuals with BC compared to the control groups. Similarity, most of the studies revealed an increased risk of BC among people with a positive history of atopic using IgE specific or prick test. However, a null association was reported in most of the asthmatic studies, and controversial results were detected in the individuals with history of food and drug allergies.

One of the possible immunological mechanisms behind the role of allergy in cancer is related to the chronic inflammation in allergic disorders, which could directly or indirectly lead to cancer development and progression.^[@bibr45-2152656719860820]^ In addition, the polarization of T cells toward Th2 in allergic diseases has been demonstrated to be pro-carcinogenesis. Previous studies reported that the epithelial cells in the atopic dermatitis secrete high level of thymic stromal lymphopoietin (TSLP).^[@bibr46-2152656719860820]^ TSLP is an IL-17 like cytokine, which activates dendrite cells (DCs) migration to the draining lymph nodes, differentiates T naive cells into the inflammatory Th2, and initiates the secretion of type 2 cytokines.^[@bibr46-2152656719860820],[@bibr47-2152656719860820]^ Studies demonstrated that TSLP fosters human breast tumor growth by promoting inflammation^[@bibr47-2152656719860820],[@bibr48-2152656719860820]^ and provides a suitable environment for the establishment, growth, and metastasis of the primary BC cell line via Th2 polarization.^[@bibr49-2152656719860820]^ Antibodies neutralizing TSLP or TSLP receptor inhibit tumor development and the secretion of IL-13 in the BC xenografts model. In addition, systemic increased types 2 cytokines such as IL-4, IL-5, and IL-13 due to Th2 polarization can contribute tumorgenesis in several ways. For instance, IL-13 induces myeloid cells to release transforming growth factor beta (TGF-β), which ultimately inhibits cytotoxic T cell activity.^[@bibr50-2152656719860820]^

Another possible mechanism behind the association of allergy--cancer is mast cells. Mast cells are the prominent cells in the immediate-type allergic reactions that reside skin and mucous membranes.^[@bibr51-2152656719860820],[@bibr52-2152656719860820]^ The role of mast cells in cancer development or protection is controversy over the studies. However, in vitro and in vivo studies support that mast cells could induce carcinogenicity through releasing several factors involved in gene instability (reactive oxygen species), angiogenesis (vascular endothelial growth factor), extracellular matrix degradation (Protease), immune suppressive (TGF-β and IL-10), and shifting immune system balance toward Th2 pathways ([Figure 1](#fig1-2152656719860820){ref-type="fig"}).^[@bibr53-2152656719860820]^ Effective mast cell targeting immunotherapy will shift the balance toward promoting the antitumor activities of mast cells.

![An overview on the role of allergy-related mechanisms in cancer development and progression. Epithelial cells in allergic disease secrete high level of TSLP, which lead to cancer initiation and progression by effecting mast cell (A) or DC (B). CTL, cytotoxic T cell; DC, dendrite cell; IL, interleukins; MDSC, myeloid-derived suppressor cells; MMP9, matrix metalloproteinase 9; PAF, platelet-activating factor; ROS, reactive oxygen species; TGF-β, transforming growth factor beta; Th, T-helper cells; TSLP, thymic stromal lymphopoietin; VEGF, vascular endothelial growth factor.](10.1177_2152656719860820-fig1){#fig1-2152656719860820}

Moreover, mast cells release several mediators such as histamine, prostaglandins, and leukotrienes. Histamine, the main mediator in the allergic disorders, plays an important role in attracting DC and skewing immune system toward Th2.^[@bibr54-2152656719860820]^ In the mammary gland, histamine plays a critical role in growth regulation, differentiation and functioning during development, pregnancy, and lactation.^[@bibr55-2152656719860820][@bibr56-2152656719860820]--[@bibr57-2152656719860820]^ High level of histamine production and secretion has been found in human breast tumors and induced mammary tumors in rats.^[@bibr58-2152656719860820][@bibr59-2152656719860820][@bibr60-2152656719860820]--[@bibr61-2152656719860820]^ In addition, histamine elevates the production of IL-10 and reduces the secretion of IL-12,^[@bibr62-2152656719860820]^ which have a beneficial effects on cancer development and progression.

In another route, mast cell--histamine promotes survival and proliferation of myeloid-derived suppressor cells (MDSCs).^[@bibr63-2152656719860820]^ Histamine can alter the cytokine milieu, transcription factors, and signaling pathways important for MDSCs accumulation. The role of MDSCs in pro-tumorgenesis has been well defined before. MDSCs release small soluble oxidizers, impair T cell antigen recognition, and ultimately cause the suppression of T cell activity and cancer development.^[@bibr63-2152656719860820][@bibr64-2152656719860820]--[@bibr65-2152656719860820]^

There are important issues in the interpretation of epidemiological studies, such as how the allergic disorders are defined in different studies (by a physician, by questionnaire, standardized, or self-reported?). In this review, we demonstrated that most of the identified studies reported no association between asthma and risk of BC, in contrast to the atopic dermatitis and allergic rhinitis. It is worth mentioning that the most impressive misclassification was predicted to appear in the asthma-specific studies due to overlapping between asthma and other chronic lung diseases. Moreover, the variable etiology of asthma, which may involve a number of immunologic and nonimmunologic factors, including allergy could affect the final results in the asthmatic studies.^[@bibr66-2152656719860820]^

The other issue is immunosuppressive and anti-inflammatory treatment in many allergic disorders. Studies reported long-term risk of malignancy among patients treated with immunosuppressive.^[@bibr67-2152656719860820]^ Moreover, animal models suggest that some antihistamines might be carcinogenic and increase the risk of cancer.^[@bibr68-2152656719860820]^ This confounding factor was less considered in the epidemiological studies, as the treatment of allergy may be critically associated with the overall risk of cancer development in allergic people.

Moreover, the disparity in the methodology of epidemiological studies such as lack of adjustment for other possible confounding or inadequate statistical power and the design of study make it challenging to compare different studies and reach a strong conclusive result. No particular difference was found between the cohort finding and the case--control results. However, an important factor, which was neglected in the interpretation of results, is that the reference group in the statistically analysis is more variable among studies, and it affects the final results for the OR in the studied patients. Therefore, considerable caution is needed in interpreting the results of epidemiological studies.

In this article, we have tried to comprehensively review the studies reporting the associations between different types of allergy and BC. However, it is not systemic review and might be susceptible to bias. Further research should reduce the heterogeneity of the studies and include high-quality evidence in order to eliminate bias and other methodological problems.

Conclusion {#sec10-2152656719860820}
==========

Bias is considered as a major issue in the observational studies, therefore interpreting of the results should be done carefully. Moreover, there are different methodological problems in different studies, which make it challenging to compare the findings and reach a strong conclusive result. However, the pattern of the results from the most studies indicates that allergic diseases might be associated with an overall risk for BC, and skewed immune system toward Th2 implies an important role in this association.
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